×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Mechanism: Mitochondrial Dysfunction in Parkinson's Disease
mechanism
4,972 words
KG: ent-mech-36e78d4a
2026-04-01
kind:mechanism
section:mechanisms
state:published
Contents
Mitochondrial Dysfunction in Parkinson's Disease
⚙
Mechanism Info
Name
Mitochondrial Dysfunction in Parkinson's Disease
Summary
Comprehensive pathway covering complex I deficiency, PINK1-Parkin mitophagy, oxidative stress, and therapeutic approaches in PD
Knowledge Graph
Related Hypotheses (30)
Microbial Inflammasome Priming Prevention
Score: 0.58
Mitochondrial Transfer Pathway Enhancement
Score: 0.44
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.48
Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Ci
Score: 0.45
Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration
Score: 0.45
Mitochondrial Calcium Buffering Enhancement via MCU Modulati
Score: 0.38
Conditional CRISPR Kill Switches for Aberrant Protein Cleara
Score: 0.45
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.67
APOE-Dependent Autophagy Restoration
Score: 0.61
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senesc
Score: 0.60
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.57
Senescent Cell Mitochondrial DNA Release
Score: 0.54
Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromat
Score: 0.52
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.51
TFAM overexpression creates mitochondrial donor-recipient gr
Score: 0.47
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.43
CX43 hemichannel engineering enables size-selective mitochon
Score: 0.41
RAB27A-dependent extracellular vesicle engineering for mitoc
Score: 0.41
Mitochondrial RNA Granule Rescue Pathway
Score: 0.40
Mitochondrial SPM Synthesis Platform Engineering
Score: 0.38
GAP43-mediated tunneling nanotube stabilization enhances neu
Score: 0.38
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m
Score: 0.35
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
Score: 0.51
Astrocytic Connexin-43 Upregulation Enhances Neuroprotective
Score: 0.45
Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy
Score: 0.43
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.40
Brain Insulin Resistance with Glucose Transporter Dysfunctio
Score: 0.40
Gap Junction Hemichannel Modulation for Controlled Mitochond
Score: 0.39
Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption
Score: 0.38
Show 25 more
Related Analyses (30)
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mitochondrial transfer between neurons and glia
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed
Show 25 more
Related Experiments (30)
Cytochrome Therapeutics
clinical · proposed · Score: 0.46
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.46
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.46
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.46
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.46
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.46
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.46
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.46
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.46
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.46
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.46
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.46
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.46
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.46
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.46
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.46
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.46
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.46
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.46
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.46
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.46
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.46
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.46
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.46
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.46
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.46
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.46
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.46
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.46
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
validation · proposed · Score: 0.46
Show 25 more